Don't want to miss the best from Business Standard?
Marksans Pharma jumped 10.30% to Rs 47.65 after the company said that its board will consider a share buyback on Friday, 8 July 2022.
As on 31 March 2022, promoters held 48.25% stake in the company.On a consolidated basis, the company reported a 62.7% fall in net profit to Rs 29.65 crore despite of a 26.6% rise in net sales to Rs 418.04 crore in Q4 FY22 over Q4 FY21.
Marksans Pharma is an Indian pharmaceutical company having a global footprint. The company's strengths lie in research, manufacturing and marketing of finished dosage pharmaceutical formulations.
Powered by Capital Market - Live News
Don't want to miss the best from Business Standard?
Disclaimer: No Business Standard Journalist was involved in creation of this content
